Moncef Slaoui, a Moderna board member and longtime drug industry executive, was awarded options to buy 18,270 shares in the company, according to Securities and Exchange Commission filings. Kaiser Health News
Read More
Pharma Money Colors Operation Warp Speed’s Quest to Defeat COVID